Department of the Army January 2013 – Federal Register Recent Federal Regulation Documents

The Department of the Army announces the availability of the draft Finding of No Significant Impact (FNSI) and final Programmatic Environmental Assessment (PEA) for Army force structure realignments that may occur from Fiscal Years (FYs) 2013-2020. The Army must achieve force reductions as it transitions from major combat operations in Iraq and Afghanistan, while reducing spending without sacrificing critical national defense capabilities. The draft FNSI considers a proposed action under which the Army's active duty end-strength would be reduced from 562,000 at the end of FY 2012 to 490,000 by FY 2020. The PEA analyzes two action alternatives: Alternative 1: Implement force reductions by inactivating a minimum of eight Brigade Combat Teams (BCTs) and realign other combat, combat support, and service support units between FY 2013 and FY 2020; and Alternative 2: Implement Alternative 1, inactivate additional BCTs, and reorganize remaining BCTs by adding an additional combat maneuver battalion and other units. The PEA also analyzes a No Action alternative under which the Army would not reduce the size of the force. The draft FNSI incorporates the PEA which does not identify any significant environmental impacts associated with either alternative, with the exception of socioeconomic impacts at some installations where a BCT is inactivated and smaller organizations realigned. The draft FNSI concludes that preparation of an Environmental Impact Statement (EIS) is not required. Final decisions as to which installations will see BCTs inactivated or units realigned have not been made. Additional site- specific NEPA analysis may be required at some installations, depending on the size of the force realignment.

In accordance with 35 U.S.C. 209(e), and 37 CFR 404.7(a)(1)(i) and 37 CFR 404.7(b)(1)(i), announcement is made of the intent to grant an exclusive, revocable license to the invention claimed in U.S. Patent No. 6,316,197, entitled ``Method of Diagnosing of Exposure to Toxic Agents by Measuring Distinct Pattern in the Levels of Expression of Specific Genes,'' issued on November 13, 2001, and foreign rights to Cascade Biotherapeutics, Inc., with its principal place of business at 4938 Hampden Lane 319, Bethesda, Maryland 20814-2914.